Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Google News
finance.yahoo.com > healthcare > articles > fda-clearance-advances-prescription-adhd-151500047.html

FDA Clearance Advances Prescription ADHD Therapeutics

1+ week, 6+ day ago   (229+ words) Dublin, Aug. 31, 2026 (GLOBE NEWSWIRE) -- The "ADHD Apps Market Size, Share & Trends Analysis Report by App Type, User Age Group, Platform, End Use, Region, and Segment Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. Global ADHD Apps Market to Reach USD…...

Google News
finance.yahoo.com > healthcare > articles > national-recovery-month-federal-data-121500691.html

National Recovery Month: New Federal Data Reveal Substance Use Treatment Gap

2+ week, 5+ day ago   (454+ words) Federal data reveal a significant substance use treatment gap as Transformed by His Promises connects Scripture, neuroscience and repeated practice to lasting change. That principle is central to Transformed by His Promises: A 12-Week Devotional for Freedom from the Psychological…...

Yahoo Finance
finance.yahoo.com > healthcare > articles > segal-trials-reinforces-leadership-acute-153300446.html

Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study

3+ week, 2+ day ago   (181+ words) MapLight Therapeutics recently announced topline results from the multicenter Phase 2 study. Segal Trials is proud to have contributed to this important clinical development program and congratulates MapLight Therapeutics, the participating investigators, study teams, and, most importantly, the patients whose participation…...

Google News
finance.yahoo.com > healthcare > articles > protagenic-therapeutics-receives-fda-pre-123000048.html

Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder

3+ week, 3+ day ago   (613+ words) Yahoo Finance Oops, something went wrong U.S. markets close in 6h 10m Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder FDA raises no objection to the Company's planned Phase 1 program design, dose-escalation approach, or CMC and nonclinical…...